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Abstract: An excess amount of glucocorticoids represents the primary and most frequent 
etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but 
also those with the endogenous form of hypercorticism, are at high risk for the loss of bone 
density, with the subsequent occurrence of pathological fractures. In this review, we summa-
rize the currently available methods of prevention and the treatment of glucocorticoid-induced 
osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that 
takes into account the risk factors typical for long-term users of glucocorticoids.
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Introduction
Glucocorticoid-induced osteoporosis (GIOP) is the most frequent and severe form of 
secondary osteoporosis.1 The prevalence of oral glucocorticoid use is 0.9% of the total 
adult population rising to 2.5% at age over 70 years.2 The most frequent indications for 
oral glucocorticoid therapy are respiratory, musculosceletal and cutaneous diseases.
Glucocorticoid therapy results in a rapid loss of bone mineral density (BMD) within 
the first weeks of treatment. The rate of loss is greatest in the first year of therapy and 
incidence of osteoporotic fractures may be as high as 20% in endogenous hypercorti-
cism and 30% to 50% in patients with long-term glucocorticoid oral use. First osteo-
porotic fractures occur as early as the first 3 to 6 months of hypercorticism.
Histomorphometric analyses of biopsies from glucocorticoid-treated individuals 
have demonstrated a reduction in bone formation at the cellular and tissue level, result-
ing in reduced bone volume and trabecular thickness. Higher doses and long-term use 
of glucocorticoids, however, also may be associated with an increase in bone resorption, 
leading to greater bone loss and disruption of cancellous bone architecture.3–5
According to several studies, it is estimated that a cumulative dose is 30 g of oral 
prednisolone per year or 5 mg (and more) of oral prednisolone per day for more than 
3 months.6,7
GIOP is most common in children, postmenopausal women, young men and patients 
with long-term immobilization.1
The association between osteoporosis and glucocorticoid therapy was made 
shortly after the first use of these drugs in humans in the 1950s, particularly in 
patients treated for asthma.8 The first population-based study of limb fractures 
was by Hooyman et al,9 who reported that the relative risk of hip, distal forearm 
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and proximal humoral fracture was doubled in a group of 
patients with rheumatoid arthritis treated with glucocor-
ticoids, compared with patients with rheumatoid arthritis 
alone. A subsequent British case-control study confirmed 
that use of glucocorticoids approximately doubles hip 
fracture risk.10
Long-term glucocorticoid use is one of the most impor-
tant osteoporosis risk factors. It is also an indication for 
densitometry.
A fracture risk assessment tool (FRAX) has been devel-
oped by World Health Organization to evaluate fracture risk 
of patients. It is based on individual patient models that 
integrate the risks associated with clinical risk factors as 
well as BMD at the femoral neck. The FRAX models have 
been developed from studying population-based cohorts 
from Europe, North America, Asia and Australia. The FRAX 
algorithms give the 10-year probability of fracture. 
Glucocorticoid use is considered as severe risk factor.
Mechanisms of bone loss in GIOP
Glucocorticoids may exert they actions on the skeleton and 
related tissues in many ways. Their overall effects depend 
on a number of factors including the dose, the duration, the 
steroid type, and the species tested. There are direct effects on 
bone that result in diminished bone formation and unchanged 
or enhanced bone resorption. The most important effect of 
glucocorticoids is suppression of bone formation, which 
probably involves several mechanisms. First, glucocorticoids 
effect the differentiation and activity of many cell types, 
including those of osteoblast lineage and other cells within 
bone. Second, glucocorticoids modulate the transcription of 
many of the genes responsible for the synthesis of matrix 
constituents by osteoblasts, such as type 1 collagen and 
osteocalcin. Third, glucocorticoids influence the synthesis and 
activity of many local acting factors that affect osteoblasts, 
including cytokines (eg, interleukin 1 and 6), and growth 
factors, especially the insulin-like growth factors (IGF-I and 
IGF-II) and several of the IGF-binding proteins (IGFBP-3, -4 
and -5). The latter effects may contribute in particular to 
the stunting of growth and retarded skeletal development in 
children treated with glucocorticoids. Recently, the role of 
apoptosis has gained prominence.13 Glucocorticoids shorten 
the lifespan of osteoblasts and osteocytes, the latter also 
being involved in the pathogenesis in glucocorticoid-induced 
osteonecrosis;14 in addition, glucocorticoids may promote 
osteoclast survival.15 Interestingly, bisphosphonates can 
reverse the pro-apoptotic effects of glucocorticoids on osteo-
blasts and osteocytes, which may contribute to their efficacy 
in preventing glucocorticoid-induced bone loss.16 In addition 
to these direct effects on bone cells, other mechanisms may 
also contribute to bone loss. Thus reduced intestinal calcium 
absorption and increased renal calcium excretion have been 
reported after the administration of glucocorticoids;17 whether 
these changes are associated with secondary hyperparathy-
roidism is controversial, most studies showing no increase in 
serum parathyroid hormone levels in glucocorticoid-treated 
individuals. Low serum testosterone levels have been reported 
in glucocorticoid-treated men and are believed to be due both 
to direct effects on the testis and indirect effects on testos-
terone production mediated via suppression of gonadotropin 
hormone secretion. Hypogonadism leads also to muscle 
decrease and increased risk of falls.18,19
The diagnosis consists of the patient’s history, clinical 
examination, densitometry and biochemical analysis (bone 
Table 1 risk factors – indications for densitometry
Estrogen defficiency
  early menopause (45 years)
  Prolonged secondary amenorrhea (1 year)
  Primary hypogonadism
Glucocorticoid use (5 mg prednisolone 3 months)  
  is expressly the indication of densitometry
Mother history of hip fracture
Low body mass index (BMi  19 kg/m2)
Diseases that leads to secondary osteoporosis
  Anorexia nervosa
  Malabsorption
  Primary hyperparathyroidism
  Diffuse diseases of connective tissue
  rheumatoid arthritis
  Chronic inflammatory bowel diseases
  Post-transplantation syndrome
  Chronic renal failure
  Hyperthyroidism
  Prolonged immobilization
  Cushing’s syndrome
  Chronic hepatopathies
  Myeloproliferative diseases
  Hereditary and metabolic bone diseases
Suspicion of osteoporosis from X-ray or finding vertebral deformity
Hip, vertebral or forearm fracure with low trauma
Decrease in stature or thoracic kyphosis
Monitoring antiresorptive therapy
Chronic medications (anticoagulants, antiepileptics,  
thyroid hormones, cytostatics)
women over 65 years
Men over 70 years
Modified from Payer et al 2007.11Drug, Healthcare and Patient Safety 2010:2 51
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turnover – typically there is decreased osteocalcin).1 In the 
context of detecting asymptomatic vertebral fractures, radiogra-
phym, eg, vertebral fracture assessment is also very important.
Prevention and treatment of GIOP
Although there are very few data on the effects of lifestyle 
interventions or modifications in GIOP, it seems reasonable 
to recommend certain measures that may reduce bone loss 
and fracture risk. These include reducing the dose of glu-
cocorticoids to a minimum, the use of alternative routes 
of administration (eg, inhaled or topical) or formulations 
(eg, budesonide), and prescription of alternative immu-
nosuppressive agents. Adequate levels of dietary calcium 
intake should be encouraged and good nutrition and normal 
body weight should be maintained where possible. In addi-
tion, individuals taking glucocorticoids should be advised 
not to smoke and to avoid alcohol abuse. Within the limits 
imposed by the underlying disease, physical exercise should 
be encouraged. Falls risk assessment and advice should be 
performed in those at increased risk of falling.21,22
Many studies report of inadequate prevention and also 
treatment of GIOP. According to the GPRD study in the 
United Kingdom,22 prophylaxis for GIOP was prescribed only 
to 14% of patients, but in the San Francisco General Hospital 
it was prescribed to only 8% of 215 patients.23
An adequate intake of calcium and vitamin D is essential 
in all preventive and also therapeutic recommendations.24 The 
recommended daily intake of calcium for an adult is 1200 
to 1500 mg per day.25 In glucocorticoid-treated patients, 
combined intake of calcium and vitamin D is more effective. 
The recommended dose of vitamin D is 800 IU per day. 
The administration of vitamin D increase calcium absorp-
tion and reduce bone resorption. Calcitriol also has a direct 
effect on osteoblasts, opposing the effects of glucocorticoids 
on osteocalcin-gene expression, and calcitriol may reverse 
glucocorticoid-indused suppression of serum osteocalcin 
concentrations.18,25
Bisphosphonates are currently the major class of 
drugs used for GIOP, in addition to their primary role in 
the treatment of postmenopausal osteoporosis. They are 
synthetic analogues of pyrophosphates that are resistant 
to the action of endogenous pyrophosphates. They have a 
high affinity for the bone mineral of the skeletal surface 
and exert an inhibitory effect on several catalytic enzymes, 
of which the most important is farnesyl diphosphate syn-
thetase, thus interfering with the mevalonate pathway of 
cholesterol formation. An insufficient prenylation results 
with a consequent dysfunction leading to apoptosis of 
osteoclasts. Osteoabsorption slows and, depending on the 
type of bisphosphonate, leads to disturbed remodeling, and 
prolongation of secondary mineralization. The following 
are bisphosponates used in the treatment of osteoporosis: 
alendronate, ibandronate, risedronate, and zoledronate, with 
pamidronate, clodronate and etidronate used in some coun-
tries.26 First effect can be seen in 6 months, which means an 
increase in bone density.27 In most countries risedronate and 
alendronate are used for treatment of GIOP. Also intravenous 
ibandronate significantly reduced vertebral fracture risk in 
patients with GIOP in small study.28 Reid recently reported 
the safety and efficacy of intravenous zoledronic acid com-
pared with oral risedronate in the prevention and treatment 
of GIOP.29,30 A single 5-mg infusion of zoledronate and daily 
oral risedronate, 5 mg, were compared in a 1-year random-
ized, double-blind, double-dummy study of patients with 
less than 3 months’ exposure of glucocorticoids and those in 
treatment for longer than 3 months. After 12 months, lumbar 
spine BMD increased significantly more with zoledronate 
than risedronate in the two subpopulations. Zolendro-
nate was also more effective than risedronate in terms of 
increasing BMD of femoral neck, trochanter and total hip. 
This superior effect was apparent at 6 months. Currently, 
bisphosphonates are considered to be the gold standard for 
the prevention and treatment in GIOP. But, unfortunately, 
no study has focused on the effect of bisphosphonates on 
reduction of vertebral fractures like in postmenopausal 
osteoporosis.31 Importantly, long-term treatment of GIOP 
with bisphosphonates is very safe.
The effectiveness of bisphosphonate treatment depends 
on patients adhering to the therapeutic regimen. Accord-
ing to the VIVA study the vast majority of patients prefer 
a once-monthly regimen – the three most popular reasons 
Table 2 FrAXTM Model – clinical risk factors (CrF)
•  Age •  Secondary osteoporosis
•  Sex –  Hypogonadism
•    Bone mineral  
density
–    Premature menopause  
(45 years)
•    Prior history of  
fracture
–    Chronic malnutrition or 
malabsorption
•  Parental history of fracture –  Osteogenesis imperfecta
•  Current smoking –  Chronic liver disease
•  Current alcohol 3 units/day –  Type i diabetes
•  rheumatoid arthritis –  Long-term hyperthyroidism
•  Glucocorticoid use  
Notes: each CrF independently contributes to fracture probability; Presence 
of 1 CrF increases probability of fracture incrementally. FrAX™. http://www.shef.
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are the need to take fewer pills, convenience and simplicity 
of treatment.32 Poor compliance to osteoporosis treatment 
is related to several different factors, including the asymp-
tomatic nature of the disease (if fractures are not present) 
and the gastrointestinal complications of bisphosphonates.32 
Therapeutic regimens with longer periods between applica-
tions are now available (ibandronate and risedronate once 
monthly by mouth, ibandronate 4 times yearly intravenous 
or intravenous zolendronate once a year) and seem to be an 
interesting way of increasing adherence.33
A very rare complication following administration of 
bisphosphonates is osteonecrosis of the jaw. It occurs most 
commonly in high doses parenterally, in the setting of poor 
dental hygiene with or without dental procedures. The risk 
with oral treatment is low. It presents with infection and 
necrosis of bone in the mandible or maxilla. It is important 
to check for good dental hygiene before administration of 
bisphosphonates, as treatment is difficult. Conservative 
management with limited debridement, antibiotics and mouth 
rinses assist healing.34 The vast majority of these cases with 
osteonecrosis of the jaw are seen in the oncology population 
receiving high doses of monthly intravenous zoledronic acid 
or pamidronate and chemotherapy.35
There are plausible scientific reasons to be vigilant about 
the potential for long-term negative effects of bisphospho-
nates on bone strenght, bone turnover and bone quality. In 
the past 4 years, several cases of unusual femoral fragility 
fractures – subtrochanteric and diaphyseal fractures – among 
patients using oral bisphosphonates (usually alendronate) 
have been reported. In general, patients experiencing such 
fractures have had bone turnover markers in the low normal 
range and bone biopsies showed markedly reduced bone 
turnover.36
The most common safety issues revolve around the effects 
of bisphosphonates on upper gastrointestinal mucosa. There is 
no doubt that the amino bisphosphonates may induce esopha-
gitis and that this problem can develop any time during the 
use of the bisphosphonate, not just at the initiation. This effect 
can be mitigated by carefully instructing the patient on the 
proper dosing of the oral bisphosphonate.35 There have been 
also reports of esophageal cancer in patients who had been 
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8 fatalities have been reported in the United States, all of them 
associated with alendronate. In Europe and Japan, 31 cases 
of esophageal cancer have been reported, with alendronate as 
the suspected drug in 21 cases. Risedronate, ibandronate and 
etidronate were the suspected drugs in 6 and a concomitant 
drug in another 4.37 If patients take the oral bisphosphonate 
according to the dosing instructions, the incidence of these 
side effects is small.38 Patients with long-term glucocorticoid 
use are at high risk of developing various side effects, so the 
intravenous form may be more appropriate.
We have only partial evidence in terms of other therapeu-
tic modalities – calcitonin, estrogens, testosterone (in men), 
raloxifen and stroncium ranelate. According to various stud-
ies, there is no evidence for a reduction in vertebral fracture 
rates, so these drugs cannot to be commended.38,39 Some 
authors suggest the administation of hydrochlorothiazide to 
reduce hypercalciuria in GIOP.40
Studies of the effect of intranasal or subcutaneous calcito-
nin on glucocorticoid-induced bone loss have produced con-
flicting results. Five studies performed in patients undergoing 
organ transplantation failed to show a significant treatment 
benefit on BMD.41–45 In the study of Valero et al, in which 
there was no control group, patients treated with calcitonin 
or cyclic etidronate showed a significant increase in lumbar 
spine BMD after 1 year of treatment (mean 6.4% and 8.2%, 
respectively).46 In several studies performed in other patient 
groups, a significant treatment benefit has been demonstrated 
in lumbar spine BMD compared to controls.47,48 However, no 
effects on spine BMD was demonstrated in three studies,49–52 
although in one study40 a significant gain in proximal femur 
BMD were demonstrated. In two of the studies in which a sig-
nificant effects on spine BMD were demonstrated, bone loss 
was however not completely prevented by calcitonin.38,49
Patients receiving prolonged glucocorticoid therapy 
may develop hypogonadism due to inhibition of secretion 
of luteinizing hormone and follicle-stimulating hormone 
from the pituitary gland, as well as direct effects on hormone 
production by the ovary and testes. All patients receiving 
long-term glucocorticoid treatment should be assessed 
for hypogonadism, and when present, this should be cor-
rected if possible. In a trial of postmenopausal women with 
rheumatoid arthritis who were taking prednisone and were 
randomized to receive either hormonal replacement therapy 
(HRT) or placebo, those who received HRT had a significant 
(3%–4%) increase in their lumbar spine BMD compared with 
controls, while there was no significant change in femoral 
neck BMD in either group.51 In a randomized controlled 
trial of injectable parathyroid hormone, postmenopausal 
women receiving long-term low-dose glucocorticoid therapy 
and HRT in the control group showed no change in BMD 
at the lumbar spine, hip, or distal radius over the course of 
1 year.53
These data suggest that HRT is adequate therapy to 
prevent bone loss in postmenopausal women receiving 
prolonged low-to-moderate-dose glucocorticoid therapy. 
Currently, however, there are no published reports on the 
efficacy of HRT in preventing bone loss at the initiation of 
glucocorticoid treatment, or the degree of the protective effect 
of HRT when moderate-to-high doses of glucocorticoids are 
used for long-term treatment.
Observational studies in premenopausal female athletes 
with menstrual irregularities suggest that women who 
receive oral contraceptives have higher adjusted bone min-
eral content and BMD than do women who do not take oral 
contraceptives.54,55 Therefore, premenopausal women who 
experience menstrual irregularities (oligo- or amenorrhea) 
while taking glucocorticoids should be offered oral contra-
ceptives or cyclic estrogen and progesterone if contraindica-
tions are not present. At this time, no data are available on the 
efficacy of selective estrogen receptor modulators (SERMs) 
in the prevention or treatment of glucocorticoid-induced bone 
loss. The SERM raloxifene is available for the prevention 
and treatment of postmenopausal osteoporosis.56,57 A SERM 
could theoretically be used to prevent glucocorticoid-induced 
bone loss in selected postmenopausal glucocorticoid-treated 
women who either have contraindications to or do not wish 
to take HRT or other antiresorptive medications.
There is less information available about men with 
hypogonadism secondary to glucocorticoid treatment.   
A randomized crossover trial demonstrated the effective-
ness of testosterone replacement therapy in 15 men with 
  glucocorticoid-treated asthma.58 All of the men had low 
serum testosterone levels prior to therapy. Lumbar spine 
BMD, but not hip BMD, was significantly increased (nearly 
4%) after 12 months of monthly intramuscular testoster-
one injections; in addition, there was an increase in lean 
body mass and a reduction in fat mass. Thus, men with 
low serum levels of testosterone who are receiving gluco-
corticoids should receive replacement therapy. Based on 
recommendations published by the American Association 
of Clinical Endocrinologists and the American College 
of Endocrinology, men with serum testosterone levels 
below the physiologic range (300 ng/mL) should receive 
replacement therapy.59 Multiple different testosterone 
preparations are available, including short- and long-acting 
intramuscular injections and transdermal patches and gels. Drug, Healthcare and Patient Safety 2010:2 54
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The goal of testosterone replacement therapy is to provide 
physiologic-range serum testosterone levels. It is important 
to emphasize that if testosterone replacement therapy is to be 
used in a hypogonadal man, the patient should be adequately 
assessed for the possibility of prostate cancer, with a digital 
rectal examination and measurement of prostate-specific 
antigen at baseline and annually thereafter. Prostate cancer 
is an absolute contraindication to testosterone replacement 
therapy.
Teriparatide is a recombinant aminoterminal fragment 
(1–34) of the human parathyroid hormone, which has a pre-
dominantly stimulating effect on bone formation. Human 
parathyroid hormone is a single chain of polypeptide with 
84 amino acids and a molecular weight of 9425 Da and 
the N-terminal region (1–34) is biologically active and suf-
ficient for regulation of mineral ion homeostasis.60 Teripa-
ratide affects the metabolism of calcium and phosphates 
in several ways – stimulation of the release of calcium and 
phosphate from the bone, stimulation of the reabsorption of 
calcium from the glomerular filtrate and loss of phosphate 
to urine, and stimulation of the renal synthesis of 1, 25-
(OH)2-vitamin D3 – and therefore the absorption of calcium 
and phosphate from the gastrointestinal tract. Patients with 
large deficits in BMD are at high risk for fracture and might 
preferentially benefit from such anabolic therapy.61–63 The 
effectiveness of the treatment with teriparatide consists of 
fracture reduction in females with severe osteoporosis and 
patient with GIOP.
Daily dose of 20 µg of teriparatide stimulates the pro-
duction of growth factors IGF-1 and TGF-β in osteoblasts 
without reduction of osteoprotegerin.
Neer and colleagues documented in a group of postmeno-
pausal females with prevalent vertebral fracture a decrease in 
risk of vertebral and non-vertebral fractures in an 18-month 
prospective study.64 The treatment was associated with sig-
nificant improvement in quality of life.
Saag have reported the results of the first 18 months 
of a 36-month prospective trial and later also results of all 
36 months.65,66 In this randomized, double-blind clinical 
trial, the primary outcome was the change from baseline 
to 36 months in BMD at the lumbar spine associated 
with the administration of daily teriparatide (at a dose of 
20 µg), compared with that of daily alendronate (at a dose 
of 10 mg), in patients with established GIOP. Prespecified 
secondary outcomes included changes in BMD at the total 
hip and markers of bone turnover, the time to changes in 
BMD at the lumbar spine and total hip, the incidence of 
vertebral and non-vertebral fractures, and adverse events.   
Ambulatory patients were eligible for enrollment if they met 
the following criteria: an age of 21 years or more, a history 
of sustained glucocorticoid therapy, and a T-score for BMD 
density at the lumbar spine or total hip of either −2.0 or 
less or −1.0 or less in addition to at least one fragility 
fracture during treatment with glucocorticoids. Sustained 
glucocorticoid therapy was defined as a mean daily dose of 
5 mg or more of prednisone or its equivalent for 3 or more 
consecutive months immediately preceding the screening 
visit. Patients were randomly assigned to receive either 
injectable teriparatide (Forteo®; Eli Lilly) at a daily dose of 
20 µg plus an oral placebo or oral alendronate (Fosamax®; 
Merck) at a daily dose of 10 mg plus an injectable placebo. 
They also received supplementation with calcium carbonate 
(at a dose of 1000 mg of elemental calcium) and vitamin 
D (at a dose of 800 IU). According to the results of the 
first 18 months, the anabolic agent teriparatide appeared 
to show significant skeletal benefits in patients with GIOP, 
compared with the bisphosphonate alendronate.67 In a 
recent trial comparing a bisphosphonate with teriparatide 
in postmenopausal women with osteoporosis, teriparatide 
therapy was associated with increased areal and volumet-
ric BMD and estimates of bone strength at the lumbar 
spine, compared with alendronate.67,68 Although the time 
course of changes in markers of bone turnover in this trial 
resembled that observed in postmenopausal women, the 
magnitude of gains in BMD in the teriparatide group was 
less than that seen previously.68 This differential response 
may reflect the characteristic ability of glucocorticoids to 
inhibit osteoblast and osteocyte function profoundly by sev-
eral mechanisms, including the stimulation of apoptosis.69 
In this study, patients in the teriparatide group had fewer 
new vertebral fractures than did patients in the alendronate 
group, although the overall number of fractures was small. 
Bisphosphonates have been associated with a reduced 
incidence of vertebral fractures in this patient population 
in randomized trials of alendronate,31,68 in pooled studies 
of risedronate,70 and in a non-randomized, open-label study 
of ibandronate.38 Although there were more non-vertebral 
fractures in the teriparatide group than in the alendronate 
group in this study, the difference was not significant. In 
previous studies of teriparatide, there was a reduction in 
non-vertebral fractures in postmenopausal women with 
osteoporosis.29,30 The standard of care for patients at risk 
for glucocorticoid-associated bone loss and osteoporosis 
includes a choice of antiresorptive agents. However, for 
patients with established osteoporosis who are at high risk 
for fracture, more aggressive and expensive therapy may be Drug, Healthcare and Patient Safety 2010:2 55
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warranted. Patients in this trial had lower BMD and more 
prevalent fractures than those in previous trials involving 
patients with GIOP, which suggests an even greater need 
for an efficacious intervention.31,69,70–74 The occurrence of 
sporadic hypercalcemia was more frequent in the teripara-
tide group than in the alendronate group.75
In a 36-month study BMD at the lumbar spine and 
femoral neck increased significantly more in the teripa-
ratide compared with alendronate group. Fewer patients 
had new radiographic vertebral fractures in the teriparatide 
than the alendronate group. The number of patients with 
new non-vertebral fractures was not significantly different 
between groups versus alendronate. There was no signifi-
cant difference between groups in the number of patients 
with 1 adverse event (91% teriparatide versus 86% 
alendronate).65,76 It should be mentioned that the therapy 
with teriparatide at various doses causes osteosarcoma 
and abnormalities in bone tissue in the rat model.73,74,77–79 
On the other hand, in the study of Neer et al and other 
major clinical trials with teriparatide no osteosarcomas 
were found.73
On the basis of the known pathophysiology of GIOP, 
teriparatide might be considered as a therapeutic strategy 
for patients at high risk for fracture.65,66
According to the literature, there are no recommenda-
tions for prevention and treatment of GIOP in children or 
premenopausal women. This treatment is always individual.63 
General principles of management include preferring other 
than oral glucocorticoids, minimizing the oral dose when 
possible and attention to nutrition, exercise and calcium and 
vitamin D status.80
Many factors influence a patient’s decision to begin 
GIOP therapies and to adhere them over time, such as the 
results and quality of evidence-based medicine studies, the 
clinician’s know-how, and the patient’s values, preferences 
and compliance. According the most national and interna-
tional studies effective therapies of GIOP such as the use 
of sufficient calcium, vitamin D and early prescription for 
bisphoshonates can lower the risk of fragility fractures. 
Despite accumulating evidence, GIOP therapies are unde-
rutilized.81
There are no multicenter, prospective, randomized, 
double-blinded clinical studies with enough patients, unlike 
postmenopausal osteoporosis, which could define effective 
treatment modalities to reduce vertebral and non-vertebral 
fractures. In clinical practice we have only trials with 
surrogate markers (like BMD, bone turnover markers) that 
can be correlated with fracture-risk reduction.
Monitoring of therapy
The role of monitoring the effects of bone-sparing agents 
in GIOP, using either BMD or biochemical markers of bone 
turnover, has not been established. Depending on the rate of 
bone loss prior to treatment, significant treatment responses 
in individuals may be detectable within 1 to 2 years using 
dual energy X-ray absorptiometric measurements of bone 
density. However, in individuals taking high doses of gluco-
corticoids, large changes in BMD may be detectable earlier 
and measurement at 6 months may be appropriate. The spine 
is the preferred site for monitoring because of the low preci-
sion error of bone density measurements at this site. Bone 
loss from the spine during the first year of glucocorticoid 
therapy may vary between 3% and 10%; since the preci-
sion error of measurements is approximately 1%, a loss of 
more than 3% (the least significant change) is likely to be 
significant. Rates of bone loss are less during established 
glucocorticoid therapy and in this situation the target is to 
increase BMD above the least significant change, ie, an 
increase of more than 3%. Bone resorption markers, such 
as N-telopeptide or C-telopeptide of type I collagen, 
show similar changes with treatment in individuals taking 
glucocorticoids to those in women with postmenopausal 
osteoporosis. However, bone resorption markers may also 
be affected by changes in inflammatory activity and hence a 
decrease following initiation of glucocorticoid therapy may 
reflect suppression of disease activity rather than reduced 
bone resorption.22
There are many recommendations for the prevention and 
treatment of GIOP. Here we describe the most important.
recommendations for the prevention  
and treatment of GiOP (American 
College of rheumatology 2001)82
The Committee recommends obtaining a baseline mea-
surement of BMD at the lumbar spine and/or hip when 
initiating long-term (ie, 6 months) glucocorticoid 
therapy. Longitudinal measurements may be repeated as 
often as every 6 months for monitoring glucocorticoid-
treated patients to detect bone loss. In patients who are 
receiving therapy to prevent bone loss, annual follow-up 
measurements are probably sufficient. These recom-
mendations divide patients into two groups in terms of 
glucocorticoid use.
A – patient beginning therapy with glucocorticoid 
(prednisone equivalent of 5 mg/day) with plans for treatment 
duration of 3 months:Drug, Healthcare and Patient Safety 2010:2 56
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–  Modify lifestyle risk factors for osteoporosis (smoking 
cessation or avoidance, reduction of alcohol consumption 
if excessive, instruct in weight-bearing physical 
exercise)
–  Initiate calcium supplementation
–  Initiate supplementation with vitamin D (plain or acti-
vated form)
–  Prescribe bisphosphonate (use with caution in premeno-
pausal women)
B – patient receiving long-term glucocorticoid therapy 
(prednisone equivalent of 5 mg/day)
–  Modify lifestyle risk factors for osteoporosis (smoking 
cessation or avoidance, reduction of alcohol consump-
tion if excessive, instruct in weight-bearing physical 
exercise)
–  Initiate calcium supplementation
–  Initiate supplementation with vitamin D (plain or acti-
vated form)
–  Prescribe treatment to replace gonadal sex hormones if 
deficient or otherwise clinically indicated
–  Measure BMD at lumbar spine and/or hip
a)  if BMD is not normal (T-score below –1.0 SD)
–    Prescribe bisphosphonate (use with caution in 
premenopausal women)
–    Consider calcitonin as second-line agent if patient 
has contraindication to or does not tolerate 
bisphosphonate therapy
b)  if BMD is normal
–    Follow up and repeat BMD measurement either 
annually or biannually.
The American Society for Bone and 
Mineral research 200483
In patients receiving prednisone more than 3 months   
5 mg/day and with risk factors of osteoporosis (premenopausal 
women, men over 50 years, low BMI, prior osteoporotic frac-
ture, high doses of glucocorticoids, diseases that leads to 
secondary osteoporosis, low calcium intake, immobilization, 
family history of osteoporosis) – measure BMD:
A – T-score below −2.5 SD
–  start treatment with oral or intravenous bishosphonates
–  calcium, vitamin D
B–T-score −1.5 to −2.5 SD
–  consider treatment with oral or intravenous bisphos-
phonates
–  calcium, vitamin D
C–T-score more than −1.5 SD
–  calcium, vitamin D
–  measure BMD after 12 months of glucocorticoid therapy.
The Dutch Society for  
rheumatology 200484
The stream diagram (Figure 2) shows the diagnostic and 
therapeutic steps in making decisions for the prevention of 
GIOP. Factors that influence this decision include the dose 
of glucocorticoids and the presence of other risk factors 
such as age, sex, previous fracture, and BMD. The main 
message is that treatment with bisphosphonates should be 
started immediately in patients at high risk (high dose of 
glucocorticoids, prevalent fracture, postmenopausal women, 
and elderly men).
In the Slovak Republic we have currently accepted rec-
ommendations for patients with long-term glucocorticoid 
use. These recommendations reflect information about the 
efficiency of  teriparatide.
recommendations for prevention  
of GiOP in the Slovak republic63
1.  Patients receiving long-term glucocorticoid therapy 
(3 months 7.5 mg prednisone/day or cumulative dose 
27 g/year) – without risk factors:
Peventive actions – reducing the dose of glucocorti-
coids to a minimum, exclusion of all risk factors, instruct 
in weight-bearing physical exercise, BMI  19, calcium 
supplementation 1000 to 1500 mg per day, vitamin D 
supplementation 800 IU per day.
Measure BMD at lumbar spine and hip:
–  T-score  −2.0 SD measure BMD after 12 months of 
glucocorticoid therapy
–  T-score  −2.0 SD treatment with bisphosphonates
–  T-score  −2.9 SD treatment with teriparatide
–  osteoporotic fracture–treatment with teriparatide
2.  Patients receiving long-term glucocorticoid therapy 
(3 months 7.5 mg prednisone/day or cumulative dose 
27 g/year) – with risk factors
Peventive actions – reducing the dose of glucocorti-
coids to a minimum, exclusion all risk factors, instruct 
in weight-bearing physical exercise, BMI  19, calcium 
supplementation 1000 to 1500 mg per day, vitamin D 
supplementation 800 IU per day.
Measure BMD at lumbar spine and hip:
–  T-score  −1.5 SD measure BMD after 12 months of 
glucocorticoid therapy
–  T-score  −1.5 SD treatment with bisphosphonates
–  T-score  −2.9 SD treatment with teriparatide
–  osteoporotic fracture – treatment with teriparatide.Drug, Healthcare and Patient Safety 2010:2 57
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Conclusion
Glucocorticoids are widely used to treat a number of medi-
cal disorders. The administration of oral glucocorticoids is 
associated with a significant increase in fracture risk at the 
hip and spine. Measurement of BMD using dual energy x-ray 
absorptiometry is currently recommended for assessment 
of fracture risk in individuals treated with glucocorticoids. 
In general, the pharmacological agents that have undergone 
assessment for the prevention and treatment of GIOP are 
similar to those used for postmenopausal osteoporosis. But, 
according to character of GIOP, the indications for treat-
ment have to be earlier in comparison with postmenopausal 
osteoporosis.
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